ConcertAI company TeraRecon has announced the Neuro Suite, an advanced clinical suite powered by artificial intelligence (AI).
The Neuro Suite is designed for disease triage and differential diagnostic insights. It also supports activation of care in neurological disease states such as neuro-oncology, multiple sclerosis and dementia.
The platform can be integrated across healthcare organizations while addressing obstacles faced by clinicians while making decisions related to chronic neurological care.
ConcertAI CEO Dr. Jeff Elton said:
“ConcertAI’s TeraRecon Eureka Clinical AI offers a portfolio of solutions from AI leaders in neurology, including Combinostics, Imaging Biometrics and Cercare, creating first-in-class capabilities and the only open AI architecture for Clinical AI. ”
Combinostics’ algorithms provide advanced brain segmentation analysis of magnetic resonance imaging (MRI) images, enabling accurate assessment of atrophy.
It incorporates additional features that help generate comprehensive reports, determine diagnostic probabilities, and distinguish between different degenerative brain conditions such as dementia and Alzheimer’s disease.
Imaging Biometric’s algorithms are designed to provide valuable insight into brain tumor oxygenation and blood flow, providing important information about active tumor areas.
This helps in diagnosis, monitoring progress, treatment planning, and evaluating post-treatment outcomes.
Cercare’s perfusion technology helps you understand blood flow and cerebral blood volume, assess neurovascular function, and gain insight into a variety of cerebrovascular and neurotumor diseases.
